Cardiovascular and Metabolic Disorders

Latest News

Efavirenz Dose Reduction Improves Lipid Profile in Adults With HIV-1

By

Endocrinology Advisor Contributing Writer

The association of lowered efavirenz dosage and reduction in LDL and total cholesterol, makes it a possible approach for treatment of patients with metabolic or cardiovascular comorbidities.

Review Suggests More Sleep May Lower Cardiometabolic Risk

Increasing the length of nightly sleep may help reduce the risk for cardiovascular disease and metabolic disorders.

RNAi Therapeutic Gets Orphan Drug Status for Familial Chylomicronemia Syndrome

By

Steve Duffy

In FCS, mutations in lipoprotein lipase lead to an accumulation of chylomicrons in plasma resulting in severe hypertriglyceridemia.

Livalo Approved for Pediatric Patients With Heterozygous Familial Hypercholesterolemia

By

Brian Park, PharmD

Livalo is indicated for pediatric patients ≥8 years old with HeFH to reduce TC, LDL-C, and Apo-B.

Evolocumab Safely Reduces Risk for CV Events in Chronic Kidney Disease

By

Endocrinology Advisor Contributing Writer

PCSK9 inhibition with evolocumab was safe and more effective than statin monotherapy in reducing LDL-C in stable individuals with moderate CKD and clinically evident atherosclerosis.

Statin Use Linked to Lower Levels of Sex Hormones in Multi-Ethnic Cohort

By

Endocrinology Advisor Contributing Writer

Considering more individuals are eligible for statin therapy based on 2018 cholesterol guidelines, it is important to examine the possibility that the medication may impair gonadal steroidogenesis.

Genetic Factors Related to Coronary Disease Linked to Several CV Conditions

By

Endocrinology Advisor Contributing Writer

Investigators examined how genetic factors associated with cardiovascular and non-cardiovascular diseases may have an effect on reported comorbid conditions.

Alirocumab Safety Profile Similar Regardless of MI, Ischemic Stroke Status

By

Brandon May

In patients with prior myocardial infarction (MI)/ischemic stroke, treatment with alirocumab is associated with a reduction in low-density lipoprotein cholesterol (LDL-C), as well as reductions in lipoprotein(a), apolipoprotein B, and non-high-density lipoprotein cholesterol (non-HDL-C), according to study results published in the Journal of Clinical Lipidology. In addition, efficacy and safety results were similar in patients…

Vitamin D, Estradiol Deficiency Have Synergistic Effect on MetS

For Chinese postmenopausal women, vitamin D (VitD) and estradiol (E2) deficiency have a synergistic effect on metabolic syndrome.

Irregular Sleep Patterns May Increase Risk for Metabolic Syndrome

Variability in sleep duration and timing is associated with higher odds of metabolic syndrome.

Low Serum Cholesterol Levels May Worsen Peripheral Nerve Damage in Type 2 Diabetes

By

Tyler Rice

Researchers examined the association between cholesterol metabolism and sciatic nerve alterations in T2D.